NLRP3 Inflammasome Expression in Gingival Crevicular Fluid of Patients with Periodontitis and Chronic Hepatitis C by Petra Surlin, Luminita Lazar, Cerasella Sincar, Dorin Nicolae Gheorghe, Dora Maria Popescu, Virgil Mihail Boldeanu, Allma Pitru, Cristina Florescu, Ion Rogoveanu

“…Patients were divided into four groups, according to their periodontal status and previously diagnosed hepatitis C, as follows: (i) CHC group, chronic hepatitis C patients; (ii) P group, periodontal disease patients, systemically healthy; (iii) CHC + P group, patients suffering from both conditions; and (iv) H group, systemically and periodontally healthy controls. …”
Get full text

Onset of Celiac Disease after Treatment of Chronic Hepatitis C with Interferon Based Triple Therapy by Amandeep Singh, Nayere Zaeri, Immanuel K. Ho

Get full text

Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels by Patricia A. Sheiner, Sander S. Florman, Sukru Emre, Thomas Fishbein, Myron E. Schwartz, Charles M. Miller, Peter Boros

“…Background: Recurrence of hepatitis C after liver transplantation is an almost universal occurrence. …”
Get full text

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program by V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina

“…To analyze the efficacy of PTV for chronic hepatitis C within the named patient program of expanded access to daclatasvir. …”
Get full text

Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C by O. V. Taratina, T. N. Krasnova, L. M. Samokhodskaya, T. N. Lopatkina, V. A. Tkachuk, N. A. Mukhin

Subjects: “…chronic hepatitis c…”
Get full text

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries by Sten H Vermund, Salima Davlidova, Syed Hani Abidi, Syed Ali, Robert Heimer, Aidana Mustafa, Dinara Begimbetova

“…Objective The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. …”
Get full text

The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity by Yujia Li, Max Xuezhong Ma, Bo Qin, Liang-Tzung Lin, Christopher D. Richardson, Jordan Feld, Ian D. McGilvray, Limin Chen

“…Ubiquitin-specific protease 18 (USP18) is involved in immunoregulation and response to interferon- (IFN-) based treatment in patients chronically infected with hepatitis C virus (HCV). We investigated whether and how its upregulation alters HCV infection. …”
Get full text

Central Portalization Correlates with Fibrosis but Not with Risk Factors for Nonalcoholic Steatohepatitis in Steatotic Chronic Hepatitis C by Hwajeong Lee, Sanaz Ainechi, Karen Dresser, Elizabeth M. Kurian

Get full text

Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C by P. O. Bogomolov, A. O. Bueverov, V. E. Bakirova, E. O. Lyusina, E. A. Fedosyina, S. V. Koblov, O. V. Sumtsova

Subjects: “…chronic hepatitis c…”
Get full text

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study by T. Berg, P. Buggisch, D. Hueppe, S. Mauss, H. Wedemeyer, G. Teuber, T. Lutz, K. Stein, S. Wegner, H. Hinrichsen

Subjects: “…hepatitis c…”
Get full text

Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan by Selena M. Sagan, Benoit Dupont, Jason Grebely, Mel Krajden, Sonya A. MacParland, Jennifer F. Raven, Sahar Saeed, Jordan J. Feld, D. Lorne Tyrrell, Joyce A. Wilson

“…Hepatitis C virus (HCV) affects at least 268,000 Canadians and causes greater disease burden than any other infectious disease in the country. …”
Get full text

PATHOPHYSIOLOGIC MECHANISMS OF THE INFLUENCE OF TISSUE RESPIRATION ENZYMES ON THE MITOCHONDRIAL FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS C by I.Y. Bagmut, S.M. Gramatiuk

Subjects: “…hepatitis c, nad/nadh2, mitochondrial fission.…”
Get full text

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C by Zehui Yan, Ke Fan, Xiaohong Wang, Qing Mao, Guohong Deng, Yuming Wang

“…The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. …”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

“…Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still open. Beneficial interferon properties include: absence of mutagenic capacity for hepatitis C virus and drug interaction, stimulation of host immune response. …”
Get full text

The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma by Hiroki Nishikawa, Akira Arimoto, Tomoko Wakasa, Ryuichi Kita, Toru Kimura, Yukio Osaki

“…We aimed to investigate the relationship between obesity and survival in hepatitis C virus-(HCV-) related hepatocellular carcinoma (HCC) patients who underwent curative surgical resection (SR). …”
Get full text

Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance by M. Ghabril, R. C. Dickson, M. Krishna, R. Lloyd, J. Aranda-Michel, A. Keaveny, R. Satyanarayana, H. Bonatti

“…Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. …”
Get full text

Telaprevir Activity is unaffected by the Q80K Polymorphism in Hepatitis C virus Genotype 1a by Stephen Shafran

Get full text

The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing by Stephen D Shafran

“…Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. …”
Get full text

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting by Vijay Gayam, Amrendra Kumar Mandal, Mazin Khalid, Osama Mukhtar, Arshpal Gill, Pavani Garlapati, Mowyad Khalid, Mohammed Mansour

“…Direct-acting antiviral (DAA) drugs have been highly effective in the treatment of chronic hepatitis C (CHC) infection. We aim to evaluate the treatment response of Sofosbuvir based DAA in CHC patients with compensated liver cirrhosis as limited data exists in the real-world community setting. …”
Get full text

Looking back into the Hepatitis C Virus epidemic dynamics from Unnao, India through phylogenetic approach by Ajit Patil, Pallavi Vidhate, Sandip Patil, Amrita Rao, Swarali Kurle, Samiran Panda

Get full text